| GO ID | GO name | Interaction type | Reference |
|---|---|---|---|
| GO:0000165 | Mapk cascade | Affects phenotype | PMID:16952276; PMID:9018116 |
| GO:0000226 | Microtubule cytoskeleton organization | Decreases phenotype | PMID:12405293 |
| GO:0001516 | Prostaglandin biosynthetic process | Increases phenotype | PMID:26863638 |
| GO:0002537 | Nitric oxide production involved in inflammatory response | Increases phenotype | PMID:18809656 |
| GO:0004602 | Glutathione peroxidase activity | Decreases phenotype | PMID:35734936 |
| GO:0004666 | Prostaglandin-endoperoxide synthase activity | Increases phenotype | PMID:35734936 |
| GO:0004784 | Superoxide dismutase activity | Decreases phenotype | PMID:29341888; PMID:35734936 |
| GO:0006007 | Glucose catabolic process | Decreases phenotype | PMID:26616219 |
| GO:0006171 | Camp biosynthetic process | Increases phenotype | PMID:38432573 |
| GO:0006309 | Apoptotic dna fragmentation | Increases phenotype | PMID:12843138; PMID:26863638; PMID:9141529; PMID:9872842 |
| GO:0006641 | Triglyceride metabolic process | Affects phenotype | PMID:35734936 |
| GO:0006693 | Prostaglandin metabolic process | Affects phenotype | PMID:35734936 |
| GO:0006695 | Cholesterol biosynthetic process | Affects phenotype | PMID:20578043; PMID:27208389; PMID:27208389; PMID:29852127; PMID:29852127; PMID:34890705 |
| GO:0006749 | Glutathione metabolic process | Affects phenotype | PMID:34165024; PMID:35734936 |
| GO:0006809 | Nitric oxide biosynthetic process | Increases phenotype | PMID:22185406 |
| GO:0006915 | Apoptotic process | Affects phenotype | PMID:10203554; PMID:18231920; PMID:9605009; PMID:10360474; PMID:10412747; PMID:10473109; PMID:10500066; PMID:10502407; PMID:11178870; PMID:11178870; PMID:16367743; PMID:16952276; PMID:11307620; PMID:11448925; PMID:11483865; PMID:11720884; PMID:11839765; PMID:12094262; PMID:12094262; PMID:15705602; PMID:16156861; PMID:12467231; PMID:12843138; PMID:12933658; PMID:15180944; PMID:15705602; PMID:15943032; PMID:16156861; PMID:16234849; PMID:16952276; PMID:17180086; PMID:17234346; PMID:17472962; PMID:17928957; PMID:18034278; PMID:18231920; PMID:18766339; PMID:18766339; PMID:20298590; PMID:18815881; PMID:19741129; PMID:19760159; PMID:20298590; PMID:20694854; PMID:7794281; PMID:9141529; PMID:9398081; PMID:9603146; PMID:9872842 |
| GO:0006954 | Inflammatory response | Increases phenotype | PMID:35734936 |
| GO:0007049 | Cell cycle | Decreases phenotype | PMID:10203554; PMID:11470239; PMID:9605009; PMID:10360474; PMID:10401660; PMID:10502407; PMID:11470239; PMID:11483865; PMID:12392621; PMID:12467231; PMID:15180944; PMID:17928957; PMID:18034278; PMID:7794281; PMID:9044834; PMID:9398081; PMID:9848777 |
| GO:0007095 | Mitotic g2 dna damage checkpoint signaling | Increases phenotype | PMID:26739623 |
| GO:0007162 | Negative regulation of cell adhesion | Increases phenotype | PMID:12405293 |
| GO:0008177 | Succinate dehydrogenase (ubiquinone) activity | Decreases phenotype | PMID:34165024 |
| GO:0008203 | Cholesterol metabolic process | Affects phenotype | PMID:32739440; PMID:35734936 |
| GO:0008219 | Cell death | Increases phenotype | PMID:10856525; PMID:11154978; PMID:16400415; PMID:20578043; PMID:24518598; PMID:29341888; PMID:9018116 |
| GO:0008283 | Cell population proliferation | Decreases phenotype | PMID:10203554; PMID:11470239; PMID:18231920; PMID:10360474; PMID:10401660; PMID:10412747; PMID:10856525; PMID:11178870; PMID:11483865; PMID:12094262; PMID:12094262; PMID:15705602; PMID:16156861; PMID:12392621; PMID:15160275; PMID:15180944; PMID:15705602; PMID:16156861; PMID:18034278; PMID:18199328; PMID:18231920; PMID:19260826; PMID:19760159; PMID:20298590; PMID:20578043; PMID:20948439; PMID:23718831; PMID:7794281; PMID:9605009; PMID:9848777 |
| GO:0008285 | Negative regulation of cell population proliferation | Increases phenotype | PMID:1988098; PMID:38432573 |
| GO:0008361 | Regulation of cell size | Decreases phenotype | PMID:29852127; PMID:9398081 |
| GO:0009410 | Response to xenobiotic stimulus | Increases phenotype | PMID:18809656 |
| GO:0010942 | Positive regulation of cell death | Increases phenotype | PMID:18809656; PMID:25578243; PMID:38432573 |
| GO:0016042 | Lipid catabolic process | Affects phenotype | PMID:29341888; PMID:35734936 |
| GO:0018158 | Protein oxidation | Increases phenotype | PMID:34165024 |
| GO:0018342 | Protein prenylation | Affects phenotype | PMID:10203554; PMID:11178870; PMID:16156861; PMID:17472962; PMID:9018116; PMID:9398081 |
| GO:0019432 | Triglyceride biosynthetic process | Increases phenotype | PMID:27208389; PMID:29852127 |
| GO:0019722 | Calcium-mediated signaling | Decreases phenotype | PMID:1827487 |
| GO:0020027 | Hemoglobin metabolic process | Decreases phenotype | PMID:28710503 |
| GO:0030154 | Cell differentiation | Affects phenotype | PMID:12843138; PMID:20694854; PMID:7794281 |
| GO:0030336 | Negative regulation of cell migration | Increases phenotype | PMID:12405293 |
| GO:0030866 | Cortical actin cytoskeleton organization | Decreases phenotype | PMID:12405293 |
| GO:0032060 | Bleb assembly | Increases phenotype | PMID:26863638 |
| GO:0034440 | Lipid oxidation | Increases phenotype | PMID:34165024 |
| GO:0036273 | Response to statin | Increases phenotype | PMID:32739440 |
| GO:0036438 | Maintenance of lens transparency | Affects phenotype | PMID:34890705 |
| GO:0043065 | Positive regulation of apoptotic process | Increases phenotype | PMID:26739623; PMID:28710503; PMID:9525472 |
| GO:0044237 | Cellular metabolic process | Affects phenotype | PMID:29341888; PMID:31311324 |
| GO:0044818 | Mitotic g2/m transition checkpoint | Increases phenotype | PMID:26739623 |
| GO:0045541 | Negative regulation of cholesterol biosynthetic process | Increases phenotype | PMID:21430599 |
| GO:0045599 | Negative regulation of fat cell differentiation | Increases phenotype | PMID:8773465 |
| GO:0045648 | Positive regulation of erythrocyte differentiation | Decreases phenotype | PMID:28710503 |
| GO:0045931 | Positive regulation of mitotic cell cycle | Increases phenotype | PMID:28710503 |
| GO:0046209 | Nitric oxide metabolic process | Affects phenotype | PMID:35734936 |
| GO:0048709 | Oligodendrocyte differentiation | Increases phenotype | PMID:20578043 |
| GO:0050729 | Positive regulation of inflammatory response | Increases phenotype | PMID:21430599 |
| GO:0051881 | Regulation of mitochondrial membrane potential | Affects phenotype | PMID:34165024 |
| GO:0051895 | Negative regulation of focal adhesion assembly | Increases phenotype | PMID:12405293 |
| GO:0060305 | Regulation of cell diameter | Affects phenotype | PMID:27208389 |
| GO:0070085 | Glycosylation | Decreases phenotype | PMID:10203554 |
| GO:0070265 | Necrotic cell death | Increases phenotype | PMID:35734936 |
| GO:0070665 | Positive regulation of leukocyte proliferation | Decreases phenotype | PMID:28710503 |
| GO:0072593 | Reactive oxygen species metabolic process | Increases phenotype | PMID:34165024 |
| GO:0090315 | Negative regulation of protein targeting to membrane | Increases phenotype | PMID:12405293 |
| GO:1900127 | Positive regulation of hyaluronan biosynthetic process | Increases phenotype | PMID:38432573 |
| GO:1900745 | Positive regulation of p38mapk cascade | Increases phenotype | PMID:26739623 |
| GO:1903035 | Negative regulation of response to wounding | Increases phenotype | PMID:36008464 |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.